Just wanting to confirm - the TAM here is calculated to be 27m children between 2-16. If we assume that a vaccination lasts a lifetime, Bayer (client) would receive the initial revenue of 26m x 100€ for the first 3 doses of the vaccinations.
How does the future revenue for this vaccine look like? Would only future children reaching the age of 2 be vaccinated, because all the older children have already had theirs?